Morningstar

Alphabet-Backed Isomorphic Labs Raises $2.1 Billion for AI Drug Development

Provided by Dow Jones

By Connor Hart 




  Isomorphic Labs raised $2.1 billion in its Series B funding round to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas. 



  The subsidiary of Google parent Alphabet said Tuesday that U.S. capital venture firm Thrive Capital once again led the funding round, which included additional participation from existing backers and new investors such as MGX, Temasek, CapitalG and the U.K. Sovereign AI Fund. 



  The London-based AI company will use the investment to advance its AI research and development and expand its team. 



  ""This funding round is a massive vote of confidence from a diverse group of top-tier international investors in our AI-first approach to drug design and development,ˮ said Chief Executive Demis Hassabis, who also helms Google's AI division DeepMind. 



  "Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential," he added. 



  Isomorphic Labs developed the AI platform AlphaFold, which can accurately predict a protein's structure in minutes--an important component of drug discovery. It has partnered with U.S. pharma giant Eli Lilly and Swiss drugmaker Novartis for drug design and development through AI. 





  Write to Connor Hart at connor.hart@wsj.com 





  (END) Dow Jones Newswires



  May 12, 2026 10:07 ET (14:07 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
The 10 Best Companies to Invest in Now
 
The stocks of these high-quality companies look cheap today. 
 
 
Tori Brovet 
 
 
 
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
 
Russ Kinnel shares investment ideas from his annual Thrilling Funds list and discusses how he screens for quality investments in a sea of options. 
 
 
Russel Kinnel and Ivanna Hampton 
 
 
 
The Top Funds for a Simpler Retirement Portfolio
 
For retirement savers and retirees, Christine Benz highlights all-in-one funds and core funds that can serve as building blocks for a streamlined portfolio. 
 
 
Christine Benz 
 
 
 
The 10 Best Dividend Stocks
 
These are the top dividend-paying stocks to buy today. 
 
 
Susan Dziubinski 
 
 
 
4 Stocks to Buy Before They Rise Further
 
Plus, the member of the triple-digit club reporting earnings this week. 
 
 
David Sekera, CFA and Susan Dziubinski 
 
 
 
 

			Sponsor Center